A single dose of the Biontech/Pfizer BNT162b2 vaccine protected elderly residents from severe COVID‐19 during a SARS‐coronavirus‐2 outbreak in a senior citizen home in Germany
Abstract Background: A total of 62/66 (93.9%) residents in a senior citizen home in Bremen, Germany, received the first dose of the Biontech/Pfizer vaccine BNT162b2 on December 27th 2020. After routine severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antigen tests showed positive results...
Saved in:
Main Authors: | Rolf Schwarzer, Sabine D. Freys, Nick Neuwinger, Nina Beikert, Bettina Eberspächer, Anke Edelmann, Marta Zuchowski, Inga Slothouwer, Angela Stein, Kathrin Theil, Peter Menzel, Jörg Hofmann |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-12-01
|
Series: | Immunity, Inflammation and Disease |
Subjects: | |
Online Access: | https://doi.org/10.1002/iid3.532 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan
by: Mitsuhiro Nagano, et al.
Published: (2024-12-01) -
New-onset bullous pemphigoid following the fifth dose of the COVID-19 vaccine Pfizer-BioNTech: A case report
by: Eman Badawod
Published: (2025-07-01) -
Basophil activation test to BNT162b2 lacks specificity for predicting allergic reactions to the mRNA vaccine
by: Sydney Ann Kee, PhD, et al.
Published: (2025-08-01) -
A macrophage attack culminating in microthromboses characterizes COVID 19 pneumonia
by: Brian S. Bull, et al.
Published: (2021-12-01) -
Highly Efficient Chemoprophylaxis of Perinatal Transmission of HIV 1 Infection in HIV-Infected Pregnant Women
by: G. A. Galegov
Published: (2020-05-01)